

Supplementary material

Table 1: Study sites and locations	page 2
Table 2: Severity scale for local reactions	page 3
Table 3: Severity scale for systemic adverse events	page 4
Table 4: Immunogenicity comparisons according to age category	page 5
Table 5: Immunogenicity comparisons according to gender	page 6
Table 6: Immunogenicity comparisons according to interval since last vaccination	page 7
Table 7: Duration of local reactions	page 8
Table 8: Duration of systemic adverse events	page 9
Table 9: Unsolicited adverse events according to MedDRA	page 10

Supplementary table 1. Study sites and ethical committees for the study.

Site No.	Site name	Location	Ethical committee
1	Hakata CL	Fukuoka	Hakata Clinic Institutional Review Board
2	Shinanozaka CL	Tokyo	Institutional review board of Shinanozaka clinic
3	Higashi-Shinjuku CL	Tokyo	P-One Clinic, Keikokai Medical Corp. IRB
4	P-One CL	Tokyo	
5	Osaka Pharmacology Clinical Research Hospital	Osaka	Medical Corporation Heishinkai OPHAC Hospital IRB
6	ToCROM	Tokyo	
7	Shin-Sapporo HP	Hokkaido	Kobori Central Clinical Research Ethics Committee
8	LUNA	Kanagawa	
9	Medimesse Sakurajyuji	Kumamoto	
10	Fukushima Medical HP	Fukushima	Fukushima Medical University Hospital Institutional Review Board
11	Juntendo HP	Tokyo	Juntendo University Hospital Institutional Review Board

Supplementary table 2. Severity scale for local reactions

Local Reaction	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially life threatening (Grade 4)
Pain	Does not interfere with activity	Repeated use of non-narcotic pain reliever > 24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	Emergency room (ER) visit or hospitalisation
Tenderness	Mild discomfort to touch	Discomfort with movement	Significant discomfort at rest	ER visit or hospitalisation
Erythema / Redness	2.5 – 5.0 cm	5.1 – 10 cm	> 10 cm	Necrosis or exfoliative dermatitis
Induration / Swelling	2.5 – 5.0 cm and does not interfere with activity	5.1 – 10 cm or interferes with activity	> 10 cm or prevents daily activity	Necrosis

Supplementary table 3. Severity scale for systemic adverse events

Systemic adverse event	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially life threatening (Grade 4)
Fever (°C)	38.0° – 38.4°	38.5° – 38.9°	39.0° – 40.0°	> 40.0°
Nausea / vomiting	No interference with activity or 1 – 2 episodes/24 hours	Some interference with activity or > 2 episodes/24 hours	Prevents daily activity, requires outpatient IV hydration	ER visit or hospitalisation for hypotensive shock
Diarrhoea	2 – 3 loose stools or < 400 g/24 hr	4 – 5 stools or 400 – 800 g/24 hr	6 or more watery stools or > 800 g/24 hr or requires outpatient IV hydration	ER visit or hospitalisation
Headache	No interference with activity	Repeated use of non- narcotic pain reliever > 24 hours or some interference with activity	Significant; any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalisation
Fatigue	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalisation
Myalgia	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalisation
Dizziness, arthralgia, chills	No interference with activity	Some interference with activity not requiring medical intervention	Prevents daily activity and requires medical intervention	ER visit or hospitalisation

Supplementary table 4.

Geometric mean titres (GMT) of neutralising antibodies and seroresponse rates (SRR) at Day 29 with non-inferiority comparisons after ARCT-154 and Comirnaty (PPS-1) – **according to age category**

Assay	Booster vaccine =	GMT (95% CI)		Seroresponse rate n / N % (95% CI)	
		ARCT-154	Comirnaty	ARCT-154	Comirnaty
Neutralising antibodies against SARS-CoV-2 Wuhan-Hu-1					
		N = 374	N = 366	244 / 374	188 / 366
< 65 years of age		5628 (4310, 7349)	3953 (3007, 5197)	65.2% (60.2, 70.1)	51.4% (46.1, 56.6)
GMT ratio or SRR difference (95% CI)		1.42 (1.25, 1.62)		13.9% (6.8, 20.8)	
		N = 11	N = 8	7 / 11	5 / 8
≥ 65 years of age		6818 (4055, 11464)	3218 (1684, 6149)	63.6% (30.8, 89.1)	62.5% (24.5, 91.5)
GMT ratio or SRR difference (95% CI)		2.12 (0.92, 4.87)		1.1% (-39.7, 43.3)	
Neutralising antibodies against SARS-CoV-2 Omicron BA.4/5					
		N = 374	N = 366	261 / 374	210 / 366
< 65 years of age		2556 (1689, 3870)	1967 (1286, 3010)	69.8% (64.9, 74.4)	57.4% (52.1, 62.5)
GMT ratio or SRR difference (95% CI)		1.30 (1.07, 1.58)		12.4% (5.5, 19.2)	
		N = 11	N = 8	8 / 11	7 / 8
≥ 65 years of age		2616 (1180, 5801)	2053 (761, 5537)	72.7% (39.0, 94.0)	87.5% (47.3, 99.7)
GMT ratio or SRR difference (95% CI)		1.27 (0.36, 4.56)		-14.8% (-48.9, 26.7)	

* GMT and GMT ratio calculated using an ANCOVA model.

Supplementary table 5.

Geometric mean titres (GMT) of neutralising antibodies and seroresponse rates (SRR) at Day 29 with non-inferiority comparisons after ARCT-154 and Comirnaty (PPS-1) – **striated by Gender**

Assay	Booster vaccine =	GMT (95% CI)		Seroresponse rate n / N % (95% CI)	
		ARCT-154	Comirnaty	ARCT-154	Comirnaty
Neutralising antibodies against SARS-CoV-2 Wuhan-Hu-1					
		N = 157	N = 162	106 / 157	89 / 162
Male		7433 (5003, 11041)	5107 (3426, 7613)	67·5% (59·6, 74·8)	54·9% (46·9, 62·8)
	GMT ratio or SRR difference (95% CI)	1·46 (1·20, 1·76)		12·6% (1·9, 23·0)	
		N = 228	N = 212	145 / 228	104 / 212
Female		4481 (3119, 6437)	3138 (2156, 4566)	63·6% (57·0, 69·8)	49·1% (42·1, 56·0)
	GMT ratio or SRR difference (95% CI)	1·43 (1·21, 1·69)		14·5% (5·3, 23·6)	
Neutralising antibodies against SARS-CoV-2 Omicron BA.4/5					
		N = 157	N = 162	109 / 157	95 / 162
Male		3001 (1592, 5657)	2549 (1345, 4833)	69·4% (61·6, 76·5)	58·6% (50·6, 66·3)
	GMT ratio or SRR difference (95% CI)	1·18 (0·86, 1·60)		10·8% (0·2, 21·1)	
		N = 228	N = 212	160 / 228	122 / 212
Female		2214 (1277, 3838)	1572 (889, 2779)	70·2% (63·8, 76·0)	57·5% (50·6, 64·3)
	GMT ratio or SRR difference (95% CI)	1·41 (1·09, 1·81)		12·6% (3·7, 21·5)	

* GMT and GMT ratio calculated using an ANCOVA model.

Supplementary table 6.

Geometric mean titres (GMT) of neutralising antibodies and seroresponse rates (SRR) at Day 29 with non-inferiority comparisons after ARCT-154 and Comirnaty (PPS-1) – **striated according to time since last vaccination**

Assay	Booster vaccine =	GMT (95% CI)		Seroresponse rate n / N % (95% CI)	
		ARCT-154	Comirnaty	ARCT-154	Comirnaty
Neutralising antibodies against SARS-CoV-2 Wuhan-Hu-1					
< 5 months since last vaccination		N = 8	N = 3	3 / 8	0 / 3
		5500 (2150, 14069)	5304 (1144, 24600)	37·5% (8·5, 75·5)	0 (0, 70·8)
	GMT ratio or SRR difference (95% CI)	1·04 (0·16, 6·64)		37·5% (-29·3, 70·6)	
≥ 5 months since last vaccination		N = 377	N = 371	248 / 377	193 / 371
		5485 (5016, 5998)	3801 (3475, 4158)	65·8% (60·8, 70·6)	52·0% (46·8, 57·2)
	GMT ratio or SRR difference (95% CI)	1·44 (1·27, 1·64)		13·8% (6·7, 20·7)	
Neutralising antibodies against SARS-CoV-2 Omicron BA.4/5					
< 5 months since last vaccination		N = 8	N = 3	4 / 8	1 / 3
		2339 (560, 9776)	5146 (498, 53218)	50·0 (15·7, 84·3)	33·3 (0·8, 90·6)
	GMT ratio or SRR difference (95% CI)	0·45 (0·03, 7·68)		16·7% (-44·4, 63·6)	
≥ 5 months since last vaccination		N = 377	N = 371	265 / 377	216 / 371
		2161 (1881, 2483)	1635 (1422, 1880)	70·3% (65·4, 74·9)	58·2% (53·0, 63·3)
	GMT ratio or SRR difference (95% CI)	1·32 (1·09, 1·61)		12·1% (5·2, 18·8)	

* GMT and GMT ratio calculated using an ANCOVA model.

Supplementary table 7.

Duration of solicited local reactions in days (Safety Set).

		ARCT-154	Comirnaty
Any solicited local reaction	n	398	395
	Mean ± SD	4·7 ± 2·4	4·5 ± 1·6
	Median	4·0	4·0
Injection site pain	n	352	358
	Mean ± SD	3·5 ± 1·4	3·6 ± 1·4
	Median	3·0	3·0
Injection site tenderness	n	388	391
	Mean ± SD	4·6 ± 2·3	4·4 ± 1·6
	Median	4·0	4·0
Injection site pain swelling	n	59	97
	Mean ± SD	3·0 ± 1·2	3·4 ± 1·7
	Median	3·0	3·0
Injection site erythema	n	52	85
	Mean ± SD	4·9 ± 2·8	3·2 ± 1·7
	Median	5·0	3·0
Injection site induration	n	52	81
	Mean ± SD	3·9 ± 1·8	3·7 ± 2·1
	Median	3·0	3·0

Supplementary table 8.Duration of solicited systemic adverse events in days

		ARCT-154	Comirnaty
Any solicited systemic AE	n events	276	255
	Mean ± SD	3·0 ± 1·4	3·0 ± 1·5
	Median	3·0	2·0
Pyrexia	n events	84	76
	Mean ± SD	2·0 ± 0·5	1·8 ± 0·6
	Median	2·0	2·0
Arthralgia	n events	112	113
	Mean ± SD	2·6 ± 1·2	2·5 ± 1·2
	Median	2·0	2·0
Chills	n events	126	103
	Mean ± SD	2·4 ± 0·9	2·2 ± 0·5
	Median	2·0	2·0
Diarrhoea	n events	28	17
	Mean ± SD	2·5 ± 1·0	3·0 ± 2·2
	Median	2·0	2·0
Dizziness	n events	25	13
	Mean ± SD	2·8 ± 1·2	2·5 ± 1·2
	Median	2·0	2·0
Headache	n events	165	125
	Mean ± SD	2·7 ± 1·1	2·8 ± 1·5
	Median	2·0	2·0
Malaise	n events	188	176
	Mean ± SD	2·9 ± 1·4	2·7 ± 1·3
	Median	2·0	2·0
Nausea	n events	21	16
	Mean ± SD	2·4 ± 0·9	2·7 ± 2·0
	Median	2·0	2·0
Vomiting	n events	2	2
	Mean ± SD	2·0 ± 0	2·0 ± 0
	Median	2·0	2·0
Myalgia	n events	123	100
	Mean ± SD	3·9 ± 1·8	3·7 ± 2·1
	Median	2·0	3·0

Supplementary table 9.

Rates of unsolicited adverse events according to MedDRA classifications in the two study groups from Day 1 to Day 29 (FAS)

	ARCT-154	Comirnaty
N =	420	408
Any unsolicited adverse event, n participants (%)	81 (19.3)	111 (27.2)
Blood and lymphatic disorders	2 (0.5)	7 (1.7)
Cardiac disorders	3 (0.7)	0
Eye disorders	2 (0.5)	2 (0.5)
Gastrointestinal disorders	11 (2.6)	13 (3.2)
General disorders and administration site conditions	28 (6.7)	47 (11.5)
Hepatobiliary disorders	1 (0.2)	0
Immune system disorders	1 (0.2)	1 (0.2)
Infections and infestations	7 (1.7)	14 (3.4)
Injury, poisoning and procedural complications	2 (0.5)	3 (0.7)
Investigations	5 (1.2)	6 (1.5)
Metabolism and nutrition disorders	1 (0.2)	0
Musculoskeletal and connective tissue disorders	10 (2.4)	15 (3.7)
Nervous system disorders	11 (2.6)	9 (2.2)
Psychiatric disorders	0	1 (0.2)
Renal and urinary disorders	0	1 (0.2)
Reproductive system and breast disorders	1 (0.2)	1 (0.2)
Respiratory, thoracic and mediastinal disorders	8 (1.9)	8 (2.0)
Skin and subcutaneous tissue disorders	6 (1.4)	5 (1.2)
Vascular disorders	1 (0.2)	3 (0.7)
